Although evolving research pertaining to incretin biology has primarily focussed on diabetes management, the concurrent anti-obesity effects and tolerability observed with pharmacological intervention has enabled pursuit of drug discovery. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.